Support is requested to permit the University of California, Los Angeles, Center for the Health Sciences (UCLA/CHS) and its affiliated hospitals and physicians to continue participation as a full member in the scientific efforts of the Southwest Oncology Group. UCLA/CHS affiliated hospitals include Olive View Medical Center (OVMC), Wadsworth Veterans Administration Medical Center (WVA), and Sepulveda Veterans Administration Medical Center (SVA) and will be referred to as The University. The University entered SWOG as a probationary member in May, 1990, and, having met SWOG requirements, received full membership status in October 1991. Using the SWOG group mechanism as the multidisciplinary focus for clinical cancer research, The University's general objectives are to; 1) strengthen clinical cancer investigations at The University and within the NCI designated Jonsson Comprehensive Cancer Center; 2) bridge the expertise in laboratory and clinical research within the University in order to strengthen SWOG's scientific efforts; and 3) become major patient contributors to the group's Phase II, Phase Ill and multimodality studies with special emphasis on recruiting minority patients to clinical trials. Specifically, The University's aim is to continue its clinical and laboratory research leadership by developing proposals in its areas of expertise, utilizing The University's basic science and clinical strengths as they apply to; 1) the use of biological agents, including monoclonal antibodies, products of molecular genetics, combination cytokine therapy, and adoptive immunotherapy, in the treatment of solid tumors; 2) the treatment of lung cancer including early detection, chemoprevention, molecular genetics, surgically resectable disease, and dose intensification/cytokine therapy; and 3) cancer control and quality of life issues including minority initiatives in breast cancer and lung cancer, survivorship issues for lymphoma patients, and behavioral modification programs. Lastly, the diverse sociocultural atmosphere of Southern California, particularly at OVMC, provides The University with a growing minority patient population. This, along with the designation of UCLA/CHS as a Comprehensive Cancer Center, attracts patients seeking new therapeutic modalities and clinical trials and provides a large pool of patients for these studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA058348-03
Application #
2099062
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-02-05
Project End
1997-12-31
Budget Start
1995-01-01
Budget End
1995-12-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Smalley, Stephen R; Benedetti, Jacqueline K; Haller, Daniel G et al. (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-33
Berglund, Ryan K; Tangen, Catherine M; Powell, Isaac J et al. (2012) Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology 79:633-7
Marshall, James R; Tangen, Catherine M; Sakr, Wael A et al. (2011) Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 4:1761-9
Swain, Sandra M; Jeong, Jong-Hyeon; Geyer Jr, Charles E et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-65
Pisters, Katherine M W; Vallières, Eric; Crowley, John J et al. (2010) Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 28:1843-9
Lara Jr, Primo N; Chansky, Kari; Shibata, Taro et al. (2010) Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0 Cancer 116:5710-5

Showing the most recent 10 out of 44 publications